lunes, 18 de marzo de 2013

Boehringer en Presidio...para firmar acuerdo.


Boehringer Ingelheim has linked up with the USA's Presidio Pharmaceuticals to look at combinations of two of its hepatitis C treatments with one of the San Francisco-based company's drugs. 

 The firms will run a Phase IIa trial to evaluate Presidio’s pan-genotypic HCV NS5A inhibitor, PPI-668 in combination with Boehringer’s HCV protease inhibitor faldaprevir and its non-nucleoside HCV polymerase inhibitor (BI207127), with or without ribavirin. The combo will be an interferon-free, all-oral, direct-acting antiviral and the 12-week study will begin in the second quarter. (Más)
Publicar un comentario